Aldolase mutant

Abstract

The invention provides a 2-deoxy-D-ribose-5-phosphate aldolase (DERA enzyme) which is capable of catalyzing an aldol condensation reaction at high performance. Compared with a wild type escherichia coli DERA enzyme, the 2-deoxy-D-ribose-5-phosphate aldolase has improved substrate resistant ability and more efficient catalytic ability. If the DERA enzyme provided by the invention is used as a catalyst, the problem of the inactivation of the DERA enzyme caused by a high-concentration chloroacetaldehyde substrate can be solved, and simultaneously, the volume of addition of the enzyme in the production process is reduced. The invention also provides a nucleic acid for coding the DERA enzyme, a recombinant expression vector containing the nucleic acid, a recombinant expression transformant containing the recombinant expression vector, a method for preparing a recombinant DERA enzyme and a catalyst for forming an optically active statin intermediate through catalysis.

Description

technical field

[0001] The invention belongs to the technical field of bioengineering, and specifically relates to an aldolase mutant and its gene, a recombinant expression vector and a recombinant expression transformant containing the gene, its recombinant enzyme and a preparation method of the recombinant enzyme, and the enzyme as a catalyst Application in the preparation of optically active statin intermediates by asymmetric aldol condensation. Background technique

[0002] statins [1] It is a new type of cholesterol-lowering drug developed in the 1980s. It acts as a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reduction inhibitor. By binding to the enzyme competitively, HMG- CoA cannot be transformed into mevalonate, an endogenous cholesterol raw material, thereby blocking the synthesis of cholesterol and reducing cholesterol levels. In addition, statins also have important functions such as lowering triglycerides and increasing high-density lipoprotein levels, so...

Images